{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T07:36:26Z","timestamp":1794641786320,"version":"4.9.1"},"reference-count":17,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T00:00:00Z","timestamp":1741824000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Allergy"],"abstract":"<jats:p>Allergic contact dermatitis (ACD), also known as allergic eczema, is a common inflammatory skin disorder that affects millions of Americans and imposes significant physical, psychological, and economic burdens. Differentiating ACD from other forms of dermatitis remains a challenge, with patch testing as the gold standard. Despite its utility, patch testing can lack diagnostic accuracy, highlighting the importance of molecular biomarkers to refine diagnosis and treatment. Advances in transcriptomics and machine-learning have enabled the identification of biomarkers involved in ACD, such as loricrin (LOR), ADAM8, CD47, BATF, SELE, and IL-37. Moreover, biomarkers such as LOR, NMF, and TEWL, may have prognostic value in evaluating therapeutic response. Emerging neurological biomarkers (neurobiomarkers), including IL-31 and TRPV1, target pathways involved in the pruritic and inflammatory responses, offering novel therapeutic targets as well. This mini review summarizes current ACD treatments, biomarkers for targeted therapies, and emphasizes the role of neurobiomarkers in ACD treatment. Additional research on the validity of the therapeutic potential of these biomarkers is necessary to improve ACD treatment and outcomes.<\/jats:p>","DOI":"10.3389\/falgy.2025.1564528","type":"journal-article","created":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T05:16:20Z","timestamp":1741842980000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Scratching the surface: biomarkers and neurobiomarkers for improved allergic contact dermatitis management"],"prefix":"10.3389","volume":"6","author":[{"given":"Akimi","family":"Sasaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Sargen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anish R.","family":"Maskey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiu-Min","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.mcna.2019.08.012","article-title":"Allergic contact dermatitis","volume":"104","author":"Nassau","year":"2020","journal-title":"Med Clin North Am"},{"key":"B2","doi-asserted-by":"publisher","first-page":"33474","DOI":"10.1073\/pnas.2009192117","article-title":"Machine-learning-driven biomarker discovery for the discrimination between allergic and irritant contact dermatitis","volume":"117","author":"Fortino","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B3","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41572-021-00271-4","article-title":"Contact dermatitis","volume":"7","author":"Scheinman","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1016\/j.jaci.2022.02.002","article-title":"Novel insights into contact dermatitis","volume":"149","author":"Johansen","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1111\/j.1365-2133.2003.05750.x","article-title":"Methylisothiazolinones elicit increased production of both T helper (Th)1- and Th2-like cytokines by peripheral blood mononuclear cells from contact allergic individuals","volume":"149","author":"Masjedi","year":"2003","journal-title":"Br J Dermatol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/cod.14391","article-title":"Epidermal biomarkers of the skin barrier in atopic and contact dermatitis","volume":"89","author":"de Boer","year":"2023","journal-title":"Contact Dermatitis"},{"key":"B7","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1111\/cod.13749","article-title":"Skin tape stripping identifies gene transcript signature associated with allergic contact dermatitis","volume":"84","author":"Tam","year":"2021","journal-title":"Contact Dermatitis"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1016\/j.jaci.2023.03.013","article-title":"Neuroimmune interactions in atopic and allergic contact dermatitis","volume":"151","author":"Liu","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"265","DOI":"10.12788\/cutis.0519","article-title":"Dupilumab for allergic contact dermatitis: an overview of its use and impact on patch testing","volume":"109","author":"Johnson","year":"2022","journal-title":"Cutis"},{"key":"B10","volume-title":"Pharmacoeconomic Review Report: Dupilumab (Dupixent): (Sanofi-Aventis Canada Inc): Indication: Moderate-to-severe atopic dermatitis (AD)","year":"2018"},{"key":"B11","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1111\/all.13942","article-title":"Natural moisturizing factor as a clinical marker in atopic dermatitis","volume":"75","author":"Nouwen","year":"2020","journal-title":"Allergy"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e01184","DOI":"10.1128\/mBio.01184-18","article-title":"Adhesion of staphylococcus aureus to corneocytes from atopic dermatitis patients is controlled by natural moisturizing factor levels","volume":"9","author":"Feuillie","year":"2018","journal-title":"mBio"},{"key":"B13","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1111\/cod.12770","article-title":"Effect of allergens and irritants on levels of natural moisturizing factor and corneocyte morphology","volume":"76","author":"Koppes","year":"2017","journal-title":"Contact Dermatitis"},{"key":"B14","doi-asserted-by":"publisher","first-page":"3526","DOI":"10.4049\/jimmunol.0900712","article-title":"Antimicrobial peptides human beta-defensins and cathelicidin LL-37 induce the secretion of a pruritogenic cytokine IL-31 by human mast cells","volume":"184","author":"Niyonsaba","year":"2010","journal-title":"J Immunol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12948-021-00165-6","article-title":"Quality of life in patients with allergic and immunologic skin diseases: in the eye of the beholder","volume":"19","author":"Di Agosta","year":"2021","journal-title":"Clin Mol Allergy"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1111\/bjd.17455","article-title":"Efficacy and safety of PAC-14028 cream\u2014a novel, topical, nonsteroidal, selective TRPV1 antagonist in patients with mild-to-moderate atopic dermatitis: a phase IIb randomized trial","volume":"180","author":"Lee","year":"2019","journal-title":"Br J Dermatol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"6955","DOI":"10.2147\/JIR.S467327","article-title":"Preclinical models of atopic dermatitis suitable for mechanistic and therapeutic investigations","volume":"17","author":"Maskey","year":"2024","journal-title":"J Inflamm Res"}],"container-title":["Frontiers in Allergy"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2025.1564528\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T05:16:23Z","timestamp":1741842983000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2025.1564528\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,13]]},"references-count":17,"alternative-id":["10.3389\/falgy.2025.1564528"],"URL":"https:\/\/doi.org\/10.3389\/falgy.2025.1564528","relation":{},"ISSN":["2673-6101"],"issn-type":[{"value":"2673-6101","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,13]]},"article-number":"1564528"}}